Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XSAT:DBP B'
s Net Margin % Range Over the Past 10 Years
Min: -58363.16 Med: -1242.59 Max: 366.42
Current: 366.42
XSAT:DBP B's Net Margin % is ranked better than 98.83% of 942
companies
in the Biotechnology industry
Industry Median: -88.295
vs XSAT:DBP B: 366.42
Double Bond Pharmaceutical International AB (XSAT:DBP B) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Double Bond Pharmaceutical International AB Net Margin % Related Terms
Double Bond Pharmaceutical International AB Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB Net Margin % Chart
Double Bond Pharmaceutical International AB Annual Data
XSAT:DBP B vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Double Bond Pharmaceutical International AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Double Bond Pharmaceutical International AB Net Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB (XSAT:DBP B) has a Net Margin % of -503.77% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Double Bond Pharmaceutical International AB and its competitors. According to the industry distribution chart, Double Bond Pharmaceutical International AB ranks #11 out of 942 companies in the Biotechnology industry, placing it in the top 1.2%.
Is Double Bond Pharmaceutical International AB's Net Margin % too high?
Double Bond Pharmaceutical International AB's current Net Margin % is -503.77%. Based on the distribution chart, Double Bond Pharmaceutical International AB ranks #11 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Double Bond Pharmaceutical International AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Double Bond Pharmaceutical International AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Double Bond Pharmaceutical International AB ranks #11 out of 942 companies for Net Margin %. This places Double Bond Pharmaceutical International AB in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Double Bond Pharmaceutical International AB and its competitors. Double Bond Pharmaceutical International AB's current Net Margin % is -503.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Double Bond Pharmaceutical International AB stock overvalued right now?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB (XSAT:DBP B) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.06, compared to a current price of kr0.14 — trading 125.8% above its estimated fair value. The current Net Margin % is -503.77%. Double Bond Pharmaceutical International AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Double Bond Pharmaceutical International AB (XSAT:DBP B), the current Net Margin % is -503.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Double Bond Pharmaceutical International AB (XSAT:DBP B) Overvalued in 2026?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB stock appears to be overvalued.
The current stock price of kr0.14 is trading 125.8% above its estimated GF Value™ of kr0.06.
GuruFocus considers Double Bond Pharmaceutical International AB to be Significantly Overvalued.
Key valuation signals for XSAT:DBP B:
Net Margin %: -503.77%
GF Value™: kr0.06 vs. price of kr0.14 (125.8% above fair value)
No single metric tells the full story. See the XSAT:DBP B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Double Bond Pharmaceutical International AB Business Description
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.
30GF Score
Get the complete analysis for XSAT:DBP B
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DBP B has been successfully added to your 
